Evidence map›Paper›PMID 40386771›Full record

ArticleFrontiers in immunology2025

Anti-PD-1 antibody enhances homeostatic proliferation-induced antitumor immunity during lymphopenia recovery.

Zike Yang, Ying Zhu, Qian Wang, Qing Lin, Yahui Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zike Yang *Department of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Ying Zhu *Department of Obstetrics and Gynecology, The Third Affiliated Hospital/The Third Clinical Medicine School of Southern Medical University, Guangzhou, China.
Qian WangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital/The Third Clinical Medicine School of Southern Medical University, Guangzhou, China.
Qing LinDepartment of Rehabilitation, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Yahui LiuDepartment of Oncology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lymphopenia induced by radiotherapy or chemotherapy can promote homeostatic proliferation of residual or adoptive lymphocytes, potentially enhancing antitumor immunity. However, this immunity diminishes rapidly with tumor progression, and the underlying mechanisms remain unclear. This study investigates the role of PD-1 signaling in homeostatic proliferation-induced antitumor immunity in malignant melanoma. Methods: We evaluated T-cell dynamics in lymphopenic mice, analyzing PD-1 expression, IFN-γ production by CD8 Results: Although T cells proliferated continuously in lymphopenic mice, IFN-γ+ CD8 Discussion: These findings indicate that the PD-1/PD-L1 axis plays a critical role in immune tolerance during homeostatic proliferation. Anti-PD-1 therapy may enhance antitumor immunity during lymphopenia recovery after chemotherapy or radiotherapy, offering a potential strategy to sustain T-cell-mediated tumor control.

Indexed as

Immune Checkpoint InhibitorsLymphopeniaProgrammed Cell Death 1 ReceptorAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationDendritic CellsFemaleHomeostasisInterferon-gammaLymphocyte ActivationMiceMice, Inbred C57BLB7-H1 AntigenImmune Checkpoint InhibitorsInterferon-gammaPdcd1 protein, mouseProgrammed Cell Death 1 Receptorantitumor immunityhomeostatic proliferationimmunotherapylymphopeniamelanomaPD-1/PD-L1

Identifiers

PMID40386771
PMCPMC12081346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.